# OnCo record nct04657991 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04657991/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04657991", "NCT04657991" ;
  schema:name "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma"@en ;
  schema:description "A phase 3 trial of Encorafenib, Binimetinib, Pembrolizumab in melanoma, run by Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04657991/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04657991> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-01-15" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/braf-v600-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04657991-eur-j-cancer-2024/> .